- United States
- /
- Chemicals
- /
- NYSE:ECL
Is Ecolab (ECL) Pricing Looked At Differently After Recent Valuation Concerns?
- Wondering if Ecolab at around US$256.99 per share is offering fair value, a premium, or a potential opportunity? This article walks through the key numbers so you can judge for yourself.
- The stock is almost flat over the short term, with returns of 0.5% over 7 days and 2.3% over 30 days. Year to date it has declined 2.2% and over the last year it has declined 3.1%, set against a 47.5% gain over 3 years and 28.8% over 5 years.
- Recent coverage around Ecolab has focused on its role as a major player in water, hygiene and infection prevention solutions, along with ongoing attention to how it manages costs and capital allocation. This context helps frame whether the current share price is mainly reflecting business quality, market sentiment, or both.
- Ecolab currently scores 1 out of 6 on our valuation checks. This article will walk through standard valuation approaches like P/E, cash flow and asset based views, then wrap up with a broader way to think about value that many investors overlook.
Ecolab scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Ecolab Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting those back to today’s value. It is essentially asking what the future stream of cash is worth in today’s dollars.
For Ecolab, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.996b. Analyst and extrapolated projections used in the model run from $1.853b in 2026 through to $3.104b in 2035, with Simply Wall St extending estimates beyond the years covered by analysts.
Bringing all those projected cash flows back to today gives an estimated intrinsic value of $208.16 per share. Compared with a current share price of about $256.99, the DCF output suggests the stock is trading at a premium, with an implied overvaluation of roughly 23.5% based on this model.
Result: OVERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Ecolab may be overvalued by 23.5%. Discover 47 high quality undervalued stocks or create your own screener to find better value opportunities.
Approach 2: Ecolab Price vs Earnings
P/E is a common way to look at valuation for profitable companies because it links what you pay for each share directly to the earnings that share produces. In general, higher growth expectations and lower perceived risk can justify a higher P/E, while slower growth and higher risk usually support a lower, more conservative P/E.
Ecolab trades on a P/E of about 34.35x, compared with roughly 26.60x for the broader Chemicals industry and about 21.91x for its peer group. Simply Wall St also calculates a Fair Ratio of 24.63x for Ecolab. This Fair Ratio is a proprietary estimate of what a reasonable P/E could be, given factors such as the company’s earnings growth profile, industry, profit margins, market value and risk characteristics.
Compared with simple industry or peer averages, the Fair Ratio aims to be more tailored to Ecolab, because it incorporates multiple business characteristics rather than just putting it in a broad bucket. Since Ecolab’s current P/E of 34.35x is above the Fair Ratio of 24.63x, the stock currently screens as trading at a richer multiple than this framework would suggest.
Result: OVERVALUED
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Upgrade Your Decision Making: Choose your Ecolab Narrative
Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in: a simple tool on Simply Wall St’s Community page that lets you connect your view of Ecolab’s story to your own forecast for revenue, earnings and margins. This then flows through to a Fair Value that you can compare with today’s share price to help decide whether the stock looks attractive or expensive to you. The tool automatically refreshes that Fair Value as new earnings, news or guidance arrive so your view stays current.
For example, one investor might build a Narrative around the higher analyst price target of US$345.00 that leans heavily on Ecolab’s pricing, digital investments and Life Sciences expansion. Another might anchor to the lower target of US$260.00 and focus more on tariff pressures, acquisition risks and softer demand. By setting these different assumptions side by side on the platform, you can see how two reasonable stories about the same company lead to very different Fair Values and decisions.
Do you think there's more to the story for Ecolab? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Ecolab might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NYSE:ECL
Ecolab
Provides water, hygiene, and infection prevention solutions and services in the United States and internationally.
Average dividend payer with acceptable track record.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Adobe: A Probabilistic Case for Undervaluation

A Capital Allocation Favorite with Structural Importance

Good foundation, but now it's all about the next steps
Recently Updated Narratives

Blindly Bullish on Indofood CBP Sukses Makmur's 5.3% Revenue Growth

CSL Investment Thesis

Investment Analysis (May 2026)
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

